202 related articles for article (PubMed ID: 26590014)
21. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Luo J; Leaw SJ; Xu Y; Zheng D
Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
[TBL] [Abstract][Full Text] [Related]
22. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
[TBL] [Abstract][Full Text] [Related]
23. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Dang J; Li G; Zang S; Zhang S; Yao L
Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer.
Scagliotti GV; Turrisi AT
Oncologist; 2003; 8(4):361-74. PubMed ID: 12897333
[TBL] [Abstract][Full Text] [Related]
25. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology.
Jalal SI; Riggs HD; Melnyk A; Richards D; Agarwala A; Neubauer M; Ansari R; Govindan R; Bruetman D; Fisher W; Breen T; Johnson CS; Yu M; Einhorn L; Hanna N
Ann Oncol; 2012 Jul; 23(7):1730-8. PubMed ID: 22156624
[TBL] [Abstract][Full Text] [Related]
26. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T
Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265
[TBL] [Abstract][Full Text] [Related]
27. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
[TBL] [Abstract][Full Text] [Related]
28. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
Dingemans AM; Bootsma G; van Baardwijk A; Reymen B; Wanders R; Brans B; Das M; Hochstenbag M; van Belle A; Houben R; Lambin P; de Ruysscher D
J Thorac Oncol; 2014 May; 9(5):710-6. PubMed ID: 24722157
[TBL] [Abstract][Full Text] [Related]
30. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
[TBL] [Abstract][Full Text] [Related]
31. Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Maráz A; Furák J; Varga Z; Fodor E; Együd Z; Borzási E; Kahán Z; Pálföldi R; Tiszlavicz L; Hideghéty K
Anticancer Res; 2013 Apr; 33(4):1737-41. PubMed ID: 23564825
[TBL] [Abstract][Full Text] [Related]
32. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Socinski MA; Blackstock AW; Bogart JA; Wang X; Munley M; Rosenman J; Gu L; Masters GA; Ungaro P; Sleeper A; Green M; Miller AA; Vokes EE
J Clin Oncol; 2008 May; 26(15):2457-63. PubMed ID: 18487565
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.
Horinouchi H; Sekine I; Sumi M; Noda K; Goto K; Mori K; Tamura T
Cancer Sci; 2013 Jan; 104(1):93-7. PubMed ID: 23004347
[TBL] [Abstract][Full Text] [Related]
35. Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
Sheng L; Cui X; Cheng L; Chen Y; Du X
Radiat Oncol; 2019 Dec; 14(1):229. PubMed ID: 31842910
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Choong NW; Mauer AM; Haraf DJ; Lester E; Hoffman PC; Kozloff M; Lin S; Dancey JE; Szeto L; Grushko T; Olopade OI; Salgia R; Vokes EE
J Thorac Oncol; 2008 Sep; 3(9):1003-11. PubMed ID: 18758303
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer.
Sakai H; Yoneda S; Kobayashi K; Komagata H; Kosaihira S; Kazumoto T; Saito Y
Lung Cancer; 2004 Feb; 43(2):195-201. PubMed ID: 14739040
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07.
Burmeister BH; Michael M; Burmeister E; Cox S; Lehman M; Wirth A; Horwood K; Sasso G; Forouzesh B; Ball D
J Thorac Oncol; 2011 Dec; 6(12):2076-82. PubMed ID: 21892106
[TBL] [Abstract][Full Text] [Related]
40. Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.
Kosmidis P; Fountzilas G; Baka S; Samantas E; Dimopoulos AM; Gogas H; Skarlos D; Papacostas P; Boukovinas J; Bakogiannis Ch; Pantelakos P; Athanasiou H; Misailidou D; Tsekeris P; Pavlidis N
Anticancer Res; 2007; 27(6C):4391-5. PubMed ID: 18214050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
